Clinical features and outcome of acquired haemophilia A Interim analysis of the Dusseldorf Study

被引:17
作者
Gheisari, R. [1 ]
Bomke, B. [1 ]
Hoffmann, T. [1 ]
Scharf, R. E. [1 ,2 ]
机构
[1] Univ Dusseldorf, Med Ctr, Hemophilia Comprehens Care Ctr, Dept Expt & Clin Hemostasis, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Bio Med Res Ctr, D-40225 Dusseldorf, Germany
来源
HAMOSTASEOLOGIE | 2010年 / 30卷 / 03期
关键词
Acquired haemophilia A; autoantibodies; morbidity; mortality; underlying disorder; FACTOR-VIII INHIBITORS; AUTOIMMUNE HEMOPHILIA; RITUXIMAB; THERAPY;
D O I
10.1055/s-0037-1619050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have performed a monocenter study on 29 consecutive patients with acquired haemophiha A who were referred for diagnosis and treatment to the Dusseldorf Haemophilia Comprehensive Care Center between March 2001 and February 2010. Patients, methods. 18 men (age. 44-86 years) and 11 women (age: 20-83 years) For laboratory evaluation, a standardized staged protocol of aPTT, FVIII. C activity and concentration, mixing studies with patient and normal plasma, and quantification of inhibitor titers (Bethesda assay) was used Diagnostic work-up included elaborate examinations for any underlying disease. Results. In 18 (62%) of the 29 patients with acquired haemophilia A, an underlying disorder was identified, including,9 patients with respiratory diseases (31%), 7 patients with autoimmune disorders (24%), one with malignancy, and one with postpartum state, while in 11 patients (38%) acquired haemophilia A remained idiopathic. Haemotherapy of bleeding, suppression or elimination of the inhibitor, and induction of immunotolerance to endogenous FVIII C were performed according to a treatment algorithm Predefined clinical endpoints were control of bleeding, eradication of the inhibitor, complete or partial remission (CR, PR), relapse, or early death (30 days). Of the 29 patients in total, 22 individuals achieved CR (76%), three had PR, one relapsed, and three died within 30 days (one of acute. myocardial infarction while on antihaemorthagic treatment, one of sepsis while on immunosuppression due to active acquired haemophilia A, one of lung bleeding in association with pre-existing pulmonary sarcoidosis). Conclusion This monocenter study demonstrates that control of life-threatening bleeding, eradication of the inhibitor, and induction of tolerance to endogenous FVIII have significantly improved the clinical outcome of acquired haemophilia A Our data also suggest a shift in underlying disorders associated with acquired haemophilia A, whereby, in comparison to published studies, a relative increase: in the proportion of patients with respiratory diseases is present.
引用
收藏
页码:156 / 161
页数:6
相关论文
共 25 条
[1]   Rituximab for autoimmune haemophilia: a proposed treatment algorithm [J].
Aggarwal, A ;
Grewal, R ;
Green, RJ ;
Boggio, L ;
Green, D ;
Weksler, BB ;
Wiestner, A ;
Schechter, GP .
HAEMOPHILIA, 2005, 11 (01) :13-19
[2]  
Boggio L N, 2001, Rev Clin Exp Hematol, V5, P389, DOI 10.1046/j.1468-0734.2001.00049.x
[3]   An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].
Boye, J ;
Elter, T ;
Engert, A .
ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535
[4]   Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients [J].
Chowdhury, P ;
Saayman, AG ;
Paulus, U ;
Findlay, GP ;
Collins, PW .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :69-73
[5]   Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation [J].
Collins, Peter W. ;
Hirsch, Sybil ;
Baglin, Trevor P. ;
Dolan, Gerard ;
Hanley, John ;
Makris, Michael ;
Keeling, David M. ;
Liesner, Ri ;
Brown, Simon A. ;
Hay, Charles R. M. .
BLOOD, 2007, 109 (05) :1870-1877
[6]   Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors [J].
Delgado, J ;
Jimenez-Yuste, V ;
Hernandez-Navarro, F ;
Villar, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (01) :21-35
[7]   Acquired factor VIII inhibitors [J].
Franchini, Massimo ;
Lippi, Giuseppe .
BLOOD, 2008, 112 (02) :250-255
[8]   Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium [J].
Gerhardt, A ;
Scharf, RE ;
Zotz, RB .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (01) :77-85
[9]  
GREEN D, 1981, THROMB HAEMOSTASIS, V45, P200
[10]  
HUBBARD AR, 2003, 02150 SSCWHO, P1